Novel mutation sites in the development of vancomycin- intermediate resistance in staphylococcus aureus

Yubing Wang, Xiaoli Li, Libo Jiang, Wentao Han, Xiangming Xie, Yi Jin, Xiaoqing He, Rongling Wu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Increased use of vancomycin has led to the emergence of vancomycin-intermediate Staphylococcus aureus (VISA). To investigate the mechanism of VISA development, 39 methicillin-susceptible strains and 3 MRSA strains were treated with vancomycin to induce non-susceptibility, and mutations in six genes were analyzed. All the strains were treated with vancomycin in vitro for 60 days. MICs were determined by the agar dilution and E-test methods. Vancomycin was then removed to assess the stability of VISA strains and mutations. Following 60 days of vancomycin treatment in vitro, 29/42 VISA strains were generated. The complete sequences of rpoB, vraS, graR, graS, walK, and walR were compared with those in the parental strains. Seven missense mutations including four novel mutations (L466S in rpoB, R232K in graS, I594M in walk, and A111T in walR) were detected frequently in strains with vancomycin MIC ≥ 12 μg/mL. Jonckheere-Terpstra trend test indicated these mutations might play an important role during VISA evolution. After the vancomycin treatment, strains were passaged to vancomycin-free medium for another 60 days, and the MICs of all strains decreased. Our results suggest that rpoB, graS, walk, and walR are more important than vraS and graR in VISA development.

Original languageEnglish (US)
Article number2163
JournalFrontiers in Microbiology
Volume7
Issue numberJAN
DOIs
StatePublished - Jan 10 2017

Fingerprint

Vancomycin Resistance
Vancomycin
Staphylococcus aureus
Mutation
Methicillin
Missense Mutation
Methicillin-Resistant Staphylococcus aureus

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Microbiology (medical)

Cite this

Wang, Yubing ; Li, Xiaoli ; Jiang, Libo ; Han, Wentao ; Xie, Xiangming ; Jin, Yi ; He, Xiaoqing ; Wu, Rongling. / Novel mutation sites in the development of vancomycin- intermediate resistance in staphylococcus aureus. In: Frontiers in Microbiology. 2017 ; Vol. 7, No. JAN.
@article{1f6cea6fbf684627a684ce27c99e64ba,
title = "Novel mutation sites in the development of vancomycin- intermediate resistance in staphylococcus aureus",
abstract = "Increased use of vancomycin has led to the emergence of vancomycin-intermediate Staphylococcus aureus (VISA). To investigate the mechanism of VISA development, 39 methicillin-susceptible strains and 3 MRSA strains were treated with vancomycin to induce non-susceptibility, and mutations in six genes were analyzed. All the strains were treated with vancomycin in vitro for 60 days. MICs were determined by the agar dilution and E-test methods. Vancomycin was then removed to assess the stability of VISA strains and mutations. Following 60 days of vancomycin treatment in vitro, 29/42 VISA strains were generated. The complete sequences of rpoB, vraS, graR, graS, walK, and walR were compared with those in the parental strains. Seven missense mutations including four novel mutations (L466S in rpoB, R232K in graS, I594M in walk, and A111T in walR) were detected frequently in strains with vancomycin MIC ≥ 12 μg/mL. Jonckheere-Terpstra trend test indicated these mutations might play an important role during VISA evolution. After the vancomycin treatment, strains were passaged to vancomycin-free medium for another 60 days, and the MICs of all strains decreased. Our results suggest that rpoB, graS, walk, and walR are more important than vraS and graR in VISA development.",
author = "Yubing Wang and Xiaoli Li and Libo Jiang and Wentao Han and Xiangming Xie and Yi Jin and Xiaoqing He and Rongling Wu",
year = "2017",
month = "1",
day = "10",
doi = "10.3389/fmicb.2016.02163",
language = "English (US)",
volume = "7",
journal = "Frontiers in Microbiology",
issn = "1664-302X",
publisher = "Frontiers Media S. A.",
number = "JAN",

}

Novel mutation sites in the development of vancomycin- intermediate resistance in staphylococcus aureus. / Wang, Yubing; Li, Xiaoli; Jiang, Libo; Han, Wentao; Xie, Xiangming; Jin, Yi; He, Xiaoqing; Wu, Rongling.

In: Frontiers in Microbiology, Vol. 7, No. JAN, 2163, 10.01.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel mutation sites in the development of vancomycin- intermediate resistance in staphylococcus aureus

AU - Wang, Yubing

AU - Li, Xiaoli

AU - Jiang, Libo

AU - Han, Wentao

AU - Xie, Xiangming

AU - Jin, Yi

AU - He, Xiaoqing

AU - Wu, Rongling

PY - 2017/1/10

Y1 - 2017/1/10

N2 - Increased use of vancomycin has led to the emergence of vancomycin-intermediate Staphylococcus aureus (VISA). To investigate the mechanism of VISA development, 39 methicillin-susceptible strains and 3 MRSA strains were treated with vancomycin to induce non-susceptibility, and mutations in six genes were analyzed. All the strains were treated with vancomycin in vitro for 60 days. MICs were determined by the agar dilution and E-test methods. Vancomycin was then removed to assess the stability of VISA strains and mutations. Following 60 days of vancomycin treatment in vitro, 29/42 VISA strains were generated. The complete sequences of rpoB, vraS, graR, graS, walK, and walR were compared with those in the parental strains. Seven missense mutations including four novel mutations (L466S in rpoB, R232K in graS, I594M in walk, and A111T in walR) were detected frequently in strains with vancomycin MIC ≥ 12 μg/mL. Jonckheere-Terpstra trend test indicated these mutations might play an important role during VISA evolution. After the vancomycin treatment, strains were passaged to vancomycin-free medium for another 60 days, and the MICs of all strains decreased. Our results suggest that rpoB, graS, walk, and walR are more important than vraS and graR in VISA development.

AB - Increased use of vancomycin has led to the emergence of vancomycin-intermediate Staphylococcus aureus (VISA). To investigate the mechanism of VISA development, 39 methicillin-susceptible strains and 3 MRSA strains were treated with vancomycin to induce non-susceptibility, and mutations in six genes were analyzed. All the strains were treated with vancomycin in vitro for 60 days. MICs were determined by the agar dilution and E-test methods. Vancomycin was then removed to assess the stability of VISA strains and mutations. Following 60 days of vancomycin treatment in vitro, 29/42 VISA strains were generated. The complete sequences of rpoB, vraS, graR, graS, walK, and walR were compared with those in the parental strains. Seven missense mutations including four novel mutations (L466S in rpoB, R232K in graS, I594M in walk, and A111T in walR) were detected frequently in strains with vancomycin MIC ≥ 12 μg/mL. Jonckheere-Terpstra trend test indicated these mutations might play an important role during VISA evolution. After the vancomycin treatment, strains were passaged to vancomycin-free medium for another 60 days, and the MICs of all strains decreased. Our results suggest that rpoB, graS, walk, and walR are more important than vraS and graR in VISA development.

UR - http://www.scopus.com/inward/record.url?scp=85012034483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012034483&partnerID=8YFLogxK

U2 - 10.3389/fmicb.2016.02163

DO - 10.3389/fmicb.2016.02163

M3 - Article

C2 - 28119680

AN - SCOPUS:85012034483

VL - 7

JO - Frontiers in Microbiology

JF - Frontiers in Microbiology

SN - 1664-302X

IS - JAN

M1 - 2163

ER -